Is Haemonetics Corp. overvalued or undervalued?

As of 8 May 2025, Haemonetics Corp. has moved from a fair to attractive valuation grade. The company is currently considered undervalued, with a P/E ratio of 22, an EV to EBITDA ratio of 13.04, and a ROE of 18.58%. In comparison, Lantheus Holdings, Inc. has a P/E of 14.54 and an EV to EBITDA of 9.83, while Bausch + Lomb Corp. is rated risky with a P/E of -16.18.
Despite recent stock performance showing a decline of 15.40% over the past year compared to a 10.26% gain in the S&P 500, Haemonetics Corp. appears to be an attractive investment opportunity based on its valuation metrics and peer comparisons. The company’s strong ROCE of 12.30% further supports its undervaluation status in the current market.